| Objective To evaluate the arrhythmia effectiveness of sakubatril/valsartan in patients with heart failure with reduced ejection fraction.Methods Pub Med,MEDLINE,EMbase,The Cochrane Library,China Knowledge Network,Wanfang,Vipshop,and China Biomedical Literature Service databases were searched for clinical studies related to sakubatril/valsartan for heart failure,and the retrieved literature was distributed from January 1,2015(when sakubatril valsartan sodium was launched)to November 12,2020(the start of this study).Endings included ventricular arrhythmias,biventricular pacing rates,atrial fibrillation,and appropriate/inappropriate shocks.Two evaluators independently screened the literature,extracted information and evaluated the quality of the included literature,and performed a meta-analysis using Review manage 5.4 software.Results A total of 5 studies with a total of 532 patients were included,and the meta-analysis showed that the incidence of ventricular arrhythmias and atrial arrhythmias was reduced in the sakubatril valsartan sodium treatment group compared with the ACEI/ARB group,with a statistically significant difference(P < 0.05),and the rate of biventricular pacing was significantly increased,with a statistically significant difference(P < 0.05),while the difference in appropriate/inappropriate electrical shocks was not statistically(P > 0.05).Conclusion Sakubatril/valsartan reduce the incidence of ventricular arrhythmias and atrial fibrillation in patients with heart failure with reduced ejection fraction,but there is no difference between appropriate and inappropriate electrical shocks.In patients with implanted three-chamber pacemakers,sakubatril/valsartan also increase the rate of biventricular pacing. |
PDF Full Text Request